Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
Karrune Woan, Maritza Lienlaf, P. Perez-Villaroel, et al.
Molecular Oncology (2015) Vol. 9, Iss. 7, pp. 1447-1457
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

Histone Deacetylase Inhibitors as Anticancer Drugs
Tomáš Eckschlager, Johana Plch, Marie Stiborová, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 7, pp. 1414-1414
Open Access | Times Cited: 1061
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Ann Lin, Christopher J. Giuliano, Ann Palladino, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 509
Open Access | Times Cited: 596
Histone deacetylase 6 in cancer
Ting Li, Chao Zhang, Shafat Hassan, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 279
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
Elizabeth Hull, McKale R. Montgomery, Kathryn J. Leyva
BioMed Research International (2016) Vol. 2016, pp. 1-15
Open Access | Times Cited: 270
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes, Alexios Matikas, Jonas Bergh, et al.
Oncogene (2018) Vol. 37, Iss. 34, pp. 4639-4661
Open Access | Times Cited: 252
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
M. Janaki Ramaiah, Anjana Devi Tangutur, M. Rajasekhar Reddy
Life Sciences (2021) Vol. 277, pp. 119504-119504
Closed Access | Times Cited: 220
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion
Devin Dersh, Jaroslav Hollý, Jonathan W. Yewdell
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 116-128
Closed Access | Times Cited: 213
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya, Sk. Abdul Amin, Nilanjan Adhikari, et al.
Pharmacological Research (2020) Vol. 163, pp. 105274-105274
Closed Access | Times Cited: 185
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1362-1391
Closed Access | Times Cited: 107
HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
Geetha Shanmugam, Sudeshna Rakshit, Koustav Sarkar
Translational Oncology (2021) Vol. 16, pp. 101312-101312
Open Access | Times Cited: 106
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Xiangyu Wu, Tianhang Li, Rui Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 67
Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
Lei Tao, Yue Zhou, Yuan Luo, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 19
The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies
Xiaowen Han, Jiayi Zhang, Weidong Li, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 2
Essential role of HDAC6 in the regulation of PD‐L1 in melanoma
Maritza Lienlaf, Patricio Perez-Villarroel, Tessa Knox, et al.
Molecular Oncology (2016) Vol. 10, Iss. 5, pp. 735-750
Open Access | Times Cited: 152
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 141
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer
Dennis O. Adeegbe, Yan Liu, Patrick H. Lizotte, et al.
Cancer Discovery (2017) Vol. 7, Iss. 8, pp. 852-867
Open Access | Times Cited: 134
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Laurence Booth, Jane L. Roberts, Andrew Poklepovic, et al.
Oncotarget (2017) Vol. 8, Iss. 47, pp. 83155-83170
Open Access | Times Cited: 122
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
Tessa Knox, Eva Sahakian, Debarati Banik, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 114
Epigenetics of malignant melanoma
Bruce Moran, Romina Silva, Antoinette S. Perry, et al.
Seminars in Cancer Biology (2017) Vol. 51, pp. 80-88
Closed Access | Times Cited: 107
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Takeshi Fukumoto, Nail Fatkhutdinov, Joseph A. Zundell, et al.
Cancer Research (2019) Vol. 79, Iss. 21, pp. 5482-5489
Open Access | Times Cited: 102
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma
Zhihao Wang, Pengchao Hu, Fang Tang, et al.
Cancer Letters (2016) Vol. 379, Iss. 1, pp. 134-142
Closed Access | Times Cited: 98
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
Sara Moufarrij, Aneil Srivastava, Stephanie Gomez, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 96
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
Thomas Strub, Flávia G. Ghiraldini, Saul Carcamo, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 92
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors
Katharina Vögerl, Nghia Ong, Johanna Senger, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 3, pp. 1138-1166
Open Access | Times Cited: 89
Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models
Yves Depetter, Silke Geurs, Rob De Vreese, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 3, pp. 735-747
Open Access | Times Cited: 87
Page 1 - Next Page

Scroll to top